chartexchange

Innovent Secures China Reimbursement Coverage Across Seven Drugs

Securities.io | Nov 13, 2026 11:08 PM EST

Innovent Biologics announced on November 14, 2026 that seven of its products had been included in China’s updated 2026 National Reimbursement Drug List (NRDL), extending national insurance reimbursement across diabetes, psoriasis, cancer and lipid-lowering treatment. Four therapies entered the list for the first time, TYVYT and Jaypirca gained newly covered indications, and SINTBILO renewed its existing agreement. The updated NRDL takes effect on January 1, 2027. Innovent said the changes…

Read original article